Selected data models

You must log in to select data models for download or further analysis.

28 Search results.
Relevance Rating New first Old first

INDIRECT OPHTHALMOSCOPY (DAY 0) CRFs Roche FVF4170G Macular Edema NCT00473382

- 6/9/17 - 1 form, 3 itemgroups, 21 items, 1 language
Itemgroups: Patient administration, INDIRECT OPHTHALMOSCOPY (DAY 0), INDIRECT OPHTHALMOSCOPY (DAY 0)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (SCREENING) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382

- 6/8/17 - 1 form, 3 itemgroups, 45 items, 1 language
Itemgroups: Patient administration, INDIRECT OPHTHALMOSCOPY (SCREENING), INDIRECT OPHTHALMOSCOPY (SCREENING)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (DAY 0) CRFs Roche FVF4168G Macular Edema NCT00473330

- 6/8/17 - 1 form, 3 itemgroups, 21 items, 1 language
Itemgroups: Patient administration, INDIRECT OPHTHALMOSCOPY (DAY 0), INDIRECT OPHTHALMOSCOPY (DAY 0)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (SCREENING) CRFs Roche FVF4168G Macular Edema NCT00473330

- 6/8/17 - 1 form, 3 itemgroups, 45 items, 1 language
Itemgroups: Patient administration, INDIRECT OPHTHALMOSCOPY (SCREENING), INDIRECT OPHTHALMOSCOPY (SCREENING)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial